Back

Cardiac biomarkers and clinical scores for risk stratification in patients with severe symptomatic aortic stenosis undergoing TAVI. Which ranks first now?

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 1 - Risk stratification and prognosis after TAVI Aortic valve disease ESC Premium Access ESC Congress 2017

About the speaker

Photo
Mrs Anja Stundl

University hospital Bonn, Bonn (Germany)

10 More presentations in this session

Presentation thumbnail
Effect of transcatheter aortic valve implantation (TAVI) in acquired von Willebrand syndrome and molecular analysis of high-molecular-weight multimers.
Doctor M. Perrone (Rome, IT)
Presentation thumbnail
Combination of pre-existing atrial fibrillation and coronary artery disease associates with poor outcome in patients who undergo TAVI
Doctor H. Hioki (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Transcatheter aortic valve replacement alters expression levels of circulating myocardial microRNAs
Doctor F. Jansen (Cologne, DE)
Abstract Slides
Presentation thumbnail
Peri-procedural myocardial injury depends on transcatheter heart valve type but does not predict mortality in patients after tavi
Mrs A. Stundl (Bonn, DE)
Abstract Slides
Presentation thumbnail
Impact of diastolic dysfunction severity on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement
Professor R. Waksman (Washington, DC, US)
Abstract

Access the full session

Session thumbnail
Poster session 1 - Risk stratification and prognosis after TAVI

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources